Update on Chronic Hand Eczema
Abstract
Hand eczema is an inflammatory skin disease that often has a chronic course. Chronic hand eczema (CHE) is defined as eczema on the hands with a disease duration of longer than three months or two or more relapses per year. During the COVID-19 pandemic, hand eczema gained attention due to the increased risk of developing particularly irritant contact dermatitis in the context of a change in hand hygiene habits and frequency of hand washing.
This has once more highlighted how important skin protection continues to be for prevention of the disease. Beyond this, new and updated guidelines are available, and a multitude of high-quality studies on hand eczema prevalence, pathogenesis and treatment have furthered our understanding of the disease and its management.
This article aims to provide an overview on recent information about hand eczema with a focus on epidemiology, quality of life, and new treatment options.
References
Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. May 2022;86(5):357-78. doi:10.1111/cod.14035
Loh EW, Yew YW. Hand hygiene and hand eczema: A systematic review and meta-analysis. Contact Dermatitis. Oct 2022;87(4):303-14.
Bauer A, Brans R, Brehler R, et al. S2k-Leitlinie diagnostik, pravention und therapie des handekzems: S2k guideline diagnosis, prevention and therapy of hand eczema. J Dtsch Dermatol Ges. Sep 2023;21(9):1054-76.
Quaade AS, Simonsen AB, Halling AS,et al. Prevalence, incidence, and severity of hand eczema in the general population - A systematic review and meta-analysis. Contact Dermatitis. Jun 2021;84(6):361-74.
Yuksel YT, Symanzik C, Christensen MO, et al. Prevalence and incidence of hand eczema in healthcare workers: A systematic review and meta-analysis. Contact Dermatitis. Apr 2024;90(4):331-42.
Haft MA, Park HH, Lee SS, et al. Pediatric chronic hand eczema: Epidemiology, clinical presentation, and management. JAAD Int. Jun 2023;11:165-73.
Simonsen AB, Dietz JB, Johansen JD. Hand eczema in Danish adolescents-Beyond atopic dermatitis. Contact Dermatitis. Jan 2024;90(1):17-22.
Silverberg JI, Warshaw EM, Maibach HI, et al. Hand eczema in children referred for patch testing: North American Contact Dermatitis Group Data, 2000-2016. Br J Dermatol. Jul 2021;185(1):185-94.
Quaade AS, Alinaghi F, Dietz JB, et al. Chronic hand eczema: A prevalent disease in the general population associated with reduced quality of life and poor overall health measures. Contact Dermatitis. Dec 2023;89(6):453-63.
Koskelo M, Sinikumpu SP, Jokelainen J, et al. Anxiety and depression in patients with hand eczema: A population-based study among 853 middle-aged subjects. Contact Dermatitis. Dec 2023;89(6):464-70.
Zalewski A, Krajewski PK, Szepietowski JC. Psychosocial consequences of hand eczema-A prospective cross-sectional study. J Clin Med. Sep 3 2023;12(17).
Zalewski A, Krajewski PK, Szepietowski JC. Prevalence and characteristics of itch and pain in patients suffering from chronic hand eczema. J Clin Med. Jun 21 2023;12(13).
Ho JSS, Molin S. A Review of existing and new treatments for the management of hand eczema. J Cutan Med Surg. Sep-Oct 2023;27(5):493-503.
Egeberg A, Schlapbach C, Haugaard JH, et al. Adverse events from topical corticosteroid use in chronic hand eczema - Findings from the Danish Skin Cohort. JAAD Int. Mar 2024;14:77-83.
Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol. Sep 2015;136(3):667-77 e7.
Bissonnette R WM, Warren RB, Agner T, et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema: pooled results of the Phase 3 DELTA 1 and 2 trials. presented at: American Academy of Dermatology Annual Meeting; 2024; San Diego, USA.
Schuttelaar ML NN, Thoning H, Bauer A. Effect of delgocitinib cream 20 mg/g on dermatology life quality index in patients with moderate to severe chronic hand eczema: pooled data from the DELTA 1 and DELTA 2 Phase 3 Trials. 2023.
Bauer A NN, Thoning H, Schuttelaar ML. Delgocitinib cream 20 mg/g improves health-related quality of life (EQ 5D) in patients with moderate to severe chronic hand eczema: pooled results from two randomised, controlled phase 3 trials. Contact Dermatitis. 2023;July 89(1):46-53
Bauer A SM, Baranowski K, Plohberger U, S et al. Delgocitinib cream reduces itch and pain in adults with moderate to severe Chronic Hand Eczema: pooled analyses of the Phase 3 DELTA 1 and 2 trials. 2024.
Simpson EL, Silverberg JI, Worm M, et al. Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. Jun 2024;90(6):1190-9.
Simpson EL, Rahawi K, Hu X, et al. Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials. J Eur Acad Dermatol Venereol. Sep 2023;37(9):1863-70.
